Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Epilepsy diagnosis after Covid-19: A population-wide study

Gabriel Westman, Johan Zelano

1. Introduction

Whether SARS-CoV-2 infects, and how it affects, the central nervous system (CNS) in the acute phase of disease has been an issue of research and discussion during the Covid-19 pandemic. The virus does not appear to be highly neurotropic or neuroinvasive, although rare cases of SARS-CoV-2 related encephalitis have been described [1].

Early reports described a substantial proportion of hospitalized patients showing affected level of consciousness, and patients in need of intensive care often presents with increased levels of brain injury biomarkers in cerebrospinal fluid, indicating axonal injury [2]. Specific engagement of the olfactory system appears relatively common, causing anosmia in a majority of patients, and changes in corresponding parts of the brain has been described [3]. Further, neurocognitive impairment is part of the complex syndrome of post-infectious disease called long covid [4]. Case reports of patients with positive SARS-CoV-2 PCR in cerebrospinal fluid (CSF) has been described, but the current consensus is that the virus does not readily infect the brain and that most CNS symptoms are mediated through immunological or metabolic mechanisms [5].

There are case reports and retrospective studies describing onset of seizures and epilepsy in conjunction with SARS-CoV-2 [6-10], but in total the literature points to acute symptomatic seizures being relatively rare and chance-associations with epilepsy-onset being hard to exclude [11]. We have previously shown that patients suffer an increased risk of epilepsy following both bacterial and viral CNS infections, most prominently after herpes simplex encephalitis and brain abscesses which can both cause loss of brain tissue and cortical scarring [12]. The objective of this study was to investigate whether the less virulent but far more common SARS-CoV-2 infection could also increase risk of epilepsy.
2. Methods

2.1. Study outline

This was a national register-based study. All individuals with a positive laboratory test for SmiNET (PCR or antigen) were considered exposed. To identify a covid-free representative cohort, Statistics Sweden identified one control per exposed matched for sex and age on 1 March 2016, before the pandemic. Cases could not be controls and controls could only be drawn once.

SmiNET identified 1237,381 individuals with a positive test between 4 Feb 2020 and 16 Dec 2021. Controls could not be found for 718 exposed that were not in the population register on their test day, and 245 individuals with possible registration errors. Individuals with a registration code for epilepsy in the national patient register (NPR) before their index date (13,636 exposed and 13,332 controls, 1.1%) were also excluded. The final cohorts consisted of 1221,801 exposed and 1223,312 controls.

2.2. Registry data collection

Based in the unique civic registration number of all Swedish individuals, data on epilepsy, comorbidities and survival were collected from the comprehensive Swedish health registers. The National Patient Register (NPR) contains all ICD-10 codes and dates of out- or inpatient hospital-based care in Sweden during the study period. The Cause of Death register contains all dates of death for individuals in Sweden. All registers were cross-referenced by the register holders and the dataset was anonymized before we were given access to it.

Epilepsy was defined as occurrence of ICD-code G40 in the NPR, seizure was defined as occurrence of R568, and status epilepticus as G41. Based on relevant ICD-codes, we identified stroke (I61, I62, I63, I69), traumatic brain injury (TBI, S01-S06, S209), brain tumor (C71, C793, D430, D330, D32), Covid-19 (U071), and procedures related to mechanical ventilation/tracheostomy (procedure codes DG02, DG016, DG018). For TBI we used only admissions; for stroke and tumours both admissions and outpatient visits were used.

2.3. Statistical analysis

As index date, we used the day of the positive test for exposed, who were followed until the end of 2021. Index date for controls was 1 March 2016, and they were followed until the end of 2017. For incidence of epilepsy, we calculated the number of epilepsy cases per 100,000 person-years after index date until the last follow-up date.

The risk of epilepsy was estimated using Cox regression with a proportional hazard assumption. The totality of data suggests that Covid-19, compared to other brain infections, is not particularly prone to cause epilepsy, at least not of a magnitude detectable at the whole population level. The overall incidence of epilepsy was very similar in those with a positive covid test and controls. It was much more common to have received mechanical ventilation among exposed and a greater proportion of individuals with a Covid-19-positive test had died at the end of follow-up.

3. Results

Demographically, the case and control groups were well matched for age and sex (Table 1). The dominating age groups were 21–60. Comorbidities were more common in the Covid-19 group than in

### Table 1

| Cohort characteristics. TBI=traumatic brain injury. |
|--------|--------|--------|--------|
|        | Covid-19 | Controls |        |
| Sex    | n      | %      | n      | %      |
| Female | 599,313 | 49.0%   | 599,583 | 49.0%   |
| Male   | 623,488 | 50.9%   | 623,729 | 51.0%   |
| Age    | 240,230 | 19.6%   | 240,031 | 19.6%   |
| 21-40  | 421,202 | 34.4%   | 421,084 | 34.4%   |
| 41-60  | 400,364 | 32.7%   | 400,052 | 32.7%   |
| 61-80  | 127,501 | 10.4%   | 128,187 | 10.5%   |
| 81-100 | 33,290  | 2.7%    | 33,743  | 2.8%    |
| 100+   | 214     | 0.0%    | 215     | 0.0%    |
| Comorbidities |        |        |        |
| Stroke | 19,190 | 1.6%   | 17,808 | 1.5% |
| TBI    | 45,505 | 3.7%   | 42,090 | 3.4% |
| Tumour | 1012   | 0.1%   | 1122   | 0.1%   |
| Mechanical ventilation | 20,414 | 1.7% | 2613 | 0.2% |
| Death  | 22,287 | 1.8%   | 14,380 | 1.2%   |

In an overall Cox regression model, belonging to the group with positive Covid-19 test was not associated with an increased risk of epilepsy (HR 1.01, 95% CI 0.91–1.12). When stratified by age (Table 3), a positive Covid-19 test was associated with a decreased risk of epilepsy in age groups 21–40 and 41–60, and increased risk of epilepsy in age groups 61–80 and 81–100 (Fig. 1).

3.2. Risk of epilepsy

In an overall Cox regression model, belonging to the group with positive Covid-19 test was not associated with an increased risk of epilepsy (HR 1.01, 95% CI 0.91–1.12). When stratified by age (Table 3), a positive Covid-19 test was associated with a decreased risk of epilepsy in age groups 21–40 and 41–60, and increased risk of epilepsy in age groups 61–80 and 81–100. When the analysis was adjusted for comorbidities, the HR of epilepsy was reduced. If mechanical ventilation was also included as a covariate, the HR associated with Covid-19 was further reduced but still statistically significant for ages 61–80, but no longer significant for ages 81–100. Judging by the slope of Kaplan-Meier curves, the increased risk of epilepsy in the older age groups was mainly caused by higher risk in close relation to the positive test (Fig. 2).

3.3. Mechanical ventilation

Given the effect of mechanical ventilation on HR of epilepsy, we assessed incidence for individuals receiving mechanical ventilation. The incidence of epilepsy for patients with an admission with both mechanical ventilation and simultaneous diagnosis of Covid-19 was 352 per 100,000 person years, for comparison, the incidence of epilepsy among individuals with mechanical ventilation for any reason was 532 per 100,000 person years among exposed and 1145 per 100,000 person years among controls.

4. Discussion

The totality of data suggests that Covid-19, compared to other brain infections, is not particularly prone to cause epilepsy, at least not of a magnitude detectable at the whole population level. The overall incidence of epilepsy was very similar in those with a positive covid test and
controls. When data were stratified for age, the picture was somewhat nuanced, showing a lower incidence after Covid-19 in younger age groups and a higher incidence after Covid-19 in the elderly. The differences were however small and could very well represent different indications and incentives for testing depending on age.

In Sweden, testing for SARS-CoV-2 was widely available and, in many situations, a negative test allowed earlier return to work or education. In the age-groups of working life age, there may therefore well be a “healthy tester” effect, meaning that healthy individuals are likely to be overrepresented among those obtaining a test. The test population under age 60 may therefore be healthier than the cross-section of the population represented in the control group. In addition, testing was ubiquitous in the health services, and all individuals admitted to hospital were tested. There will therefore be an association between a positive test and admission for any reason, which could have resulted in the higher risk of epilepsy seen in the older age groups. Indeed, Kaplan-Meier curves indicated that the increased risk in this age group was temporally closely related to the positive test. Markers of hospitalization and severe disease - illustrated by higher rates of mechanical ventilation and death - were more common in the cohort with Covid-19.

In the Cox regression model, we could not find an increased risk of epilepsy overall. The age groups showed risks in keeping with the incidence results. Interestingly, when the model was adjusted for comorbidities and ventilation, the increased HRs in older age groups were altered towards 1.0 indicating that confounding by comorbidities could be partly responsible for the increased risk observed for SARS-CoV-2 positive patients.

Need of respiratory support was a clear risk factor of subsequent epilepsy, both before and during the onset of the SARS-CoV-2 pandemic. The highest incidence was seen in the control population, in patients that were admitted with mechanical ventilation before the pandemic. This risk exceeded the risk of patients with Covid-19 admitted during the pandemic, indicating that Covid-19 patients receiving intensive care actually have a lower risk of developing epilepsy than other ICU patients. This is not surprising, since the comparison is in effect one between patients with intensive care for a primarily respiratory problem and patients with intensive care for a wide range of severe medical conditions including those affecting the brain.

Importantly, our results should not be interpreted as evidence that Covid-19 can never cause epilepsy. There is an emerging body of literature suggesting that severe Covid-19 can cause brain damage, via stroke, metabolic deregulation or immunologic mechanism that are not yet fully elucidated [11,13]. All brain-injuring processes can cause epilepsy, so in individual cases cortical or large brain lesions may well be epileptogenic. Also, it is important to stress the short-term nature of the data available. The risk of epilepsy is highest soon after brain lesions, but a slightly elevated risk persists for extended periods of time after CNS infections or trauma [12,14–16]. Similar long-term effects of Covid are

### Table 2
Incidence of epilepsy after cohort entry. P-y = person years.

|            | Covid-19 |            | Controls |            |
|------------|----------|------------|----------|------------|
|            | n        | P-y        | n/100,000 | n          | P-y        | n/100,000 |
| All        | 639      | 1024,721   | 62       | 1255       | 2232,283   | 56        |
| Male sex   | 339      | 495,017    | 68       | 659        | 1094,189   | 60        |
| Women      | 300      | 529,704    | 57       | 596        | 1138,094   | 52        |
| Age        |          |            |          |            |            |           |
| 0 - 20     | 94       | 175,270    | 54       | 257        | 440,520    | 58        |
| 21 - 40    | 101      | 364,546    | 28       | 285        | 772,497    | 37        |
| 41 - 60    | 135      | 351,178    | 38       | 352        | 732,751    | 48        |
| 61 - 80    | 227      | 110,127    | 191      | 263        | 232,014    | 113       |
| 81 - 100   | 82       | 25,490     | 349      | 98         | 54,256     | 181       |
| 101+       | 0        | 0          | 0        | 0          | 0          | 0         |

### Table 3
Hazard ratio (HR) for epilepsy in different age groups by Cox regression. *Adjusted for stroke, traumatic brain injury (TBI), tumor. **Adjusted for stroke, TBI, tumor and mechanical ventilation.

|            | Unadjusted | Adjusted* | Adjusted** |
|------------|------------|-----------|------------|
| Age        | HR         | 95% CI    | HR         | 95% CI    | HR         | 95% CI    |
| 0 - 20     | 0.84       | 0.65-1.09 | 0.84       | 0.65-1.08 | 0.80       | 0.62-1.04 |
| 21 - 40    | 0.63       | 0.49-0.80 | 0.62       | 0.49-0.79 | 0.59       | 0.46-0.75 |
| 41 - 60    | 0.78       | 0.63-0.97 | 0.80       | 0.65-0.99 | 0.65       | 0.52-0.81 |
| 61 - 80    | 1.66       | 1.37-2.02 | 1.50       | 1.24-1.82 | 1.28       | 1.05-1.57 |
| 81 - 100   | 1.77       | 1.30-2.42 | 1.51       | 1.10-2.05 | 1.34       | 0.97-1.84 |

### Fig. 1
Incidence of epilepsy after cohort entry per 100,000 person years, comparing Covid-19 exposed subjects and non-infected controls.

### Fig. 2
Kaplan-Meier curves of epilepsy in the different age groups, compared to the non-infected controls.
not yet possible to investigate. What our study does indicate is that in the short term the pandemic does not seem to have caused an increase in epilepsy diagnoses on a population-wide scale in Sweden.

Declaration ofCompeting Interest

JZ reports honoraria from UCB and Eisai for non-branded education, and as employee of Sahlgrenska university hospital (no personal compensation) being investigator in clinical trials sponsored by UCB, SK-life science, GW Pharma, and Bial.

Acknowledgment

Samuel Håkansson for validation of epilepsy diagnosis search in the patient register. Johan Zelano is supported by grants from the Swedish Society of Medicine and the Swedish Society of Medical Research. Both authors are supported by ALF-funds from the Swedish state.

References

[1] Siow I, Lee KS, Zhang JJY, Safaﬁ SE, Ng A. Encephalitis as a neurological complication of COVID-19: a systematic review and meta-analysis of incidence, outcomes, and predictors. Eur J Neurol 2021;28:3491–502.

[2] Zeiterberg H, Smith DH, Blemow K. Biomarkers of mild traumatic brain injury in cerebrospinal ﬂuid and blood. Nat Rev Neurosci 2013;9:201–10.

[3] Lechien JR, Chiensa–Estomba CM, De Slati DR, Horel M, Le Bon SD, Rodriguez A, Dequanter D, Blecic S, El Aﬁa F, Distinguin I, Chekkouri–Idrissi Y, Hans S, Delgado IL, Calvo–Henriquez C, Lavigne P, Falanga C, Barilari MR, Cammaroto G, Khalife M, Leich P, Souchay C, Rossi C, Journe F, Hsieh J, Edjlali M, Ris L, Lovato A, De Filippis C, Coppee F, Fakhry N, Ayad T, Saussez S. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to–moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 2020;277:2251–61.

[4] Guo F, Benito Ballesteros A, Yeung SP, Liu R, Saha A, Curtis L, Kaser M, Haggard MP, Cheke LG. COVCOG 1: factors predicting physical, neurological and cognitive symptoms in long COVID in a community sample. a ﬁrst publication from the COVID and cognition study. Front Aging Neurosci 2022;14:804922.

[5] Bauer L, Lakono BM, de Vrij FMS, Kushner SA, HarschniQ O, van Riel D. The neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2. Trends Neurosci 2022;45:258–68.

[6] Abdulsalam MA, Abdulsalam AJ, Shehab D. Generalized status epilepticus as a possible manifestation of COVID-19. Acta Neurol Scand 2020.

[7] Anand P, Al–Faraj A, Sader E, Dashkoff J, Abdennadher M, Murugesan R, Cervantes–Arlanzon AM, Daneshmand A. Seizure as the presenting symptom of COVID-19: a retrospective case series. Epilepsy Behav 2020;112:107335.

[8] Bhatta S, Sayed A, Ranabhakt B, Bhatta R, Acharya Y. New–onset seizure as the only presentation in a child with COVID–19. Cureus 2020;12:e8820.

[9] Lyons S, O’Kelly B, Woods S, Rowan C, Brady D, Sheehan G, Smyth S. Seizure with CSF lymphocytosis as a presenting feature of COVID–19 in an otherwise healthy young man. Seizure 2020;80:113–4.

[10] Somani S, Patti S, Gaston T, Chitlangia A, Agnihotri S. De Novo status epilepticus in patients with COVID–19. Acta Neurol Scand 2020;122:1238–40.

[11] Vohora D, Jain S, Tripathi M, Potschka H. COVID–19 and seizures: is there a link? Epilepsia 2020.

[12] Zelano J, Westman G. Epilepsy after brain infections in adults: a register–based population–wide study. Epi Rev Neurology 2020.

[13] Emami A, Fadakar N, Akbari A, Lofii M, Farazdaghi M, Javanmard F, Rezaei T, Asadi–Pooya AA. Seizure in patients with COVID–19. Neurol Sci 2020.

[14] Christensen J, Pedersen MG, Pedersen CB, Sidfenius P, Olsen J, Vestergaard M. Long–term risk of epilepsy after traumatic brain injury in children and young adults: a population–based cohort study. Lancet 2009;373:1105–10.

[15] Ahlers FS, Benros ME, Dreier JW, Christensen J. Infections and the risk of epilepsy in children and young adults: a nationwide study. Epilepsia 2019;0:275–83.

[16] Karlander M, Ljungqvist J, Zelano J. Post–traumatic epilepsy in adults: a nationwide register–based study. J Neurol Neurosurg Psychiatry 2021.